C3539881||Interferon-γ
C0242629||Diabetogenic CD8(+) T-Cell Effector
C0011854||Type 1 Diabetes
C0011854||Type 1 diabetes
C2986594||NOD mouse model
C0039215||CD4(+)
C0242629||CD8(+) T cells
C3539881||interferon-γ
C3539881||interferon-γ
C0079189||cytokine
C3539881||interferon-γ
C1817959||tolerance-induction
C1704259||pathways
C3539881||interferon-γ
C1326120||activation
C0242629||diabetogenic CD8(+) T cells
C0242629||CD8(+) T cells
C1171362||transgenically expressing
C0011847||diabetogenic
C1863012||AI4
C0034790||T-cell receptor
C0012634||disease
C0085243||unmanipulated NOD
C3539881||interferon-γ
C0085243||NOD, mice
C1863012||AI4
C0039194||T cells
C0596290||proliferation
C0085243||NOD
C3539881||interferon-γ
C0012634||Disease
C3539881||interferon-γ
C0024264||lymphocyte
C0242629||diabetogenic CD8(+) T-cell
C0007613||responses
C0040300||nonlymphoid
C0007634||cell population
C0039194||T cells
C0287920||STAT1
C0255034||STAT4
C1171362||expression
C1863012||AI4
C0039194||T cells
C3539881||interferon-γ
C1326120||activation
C0596402||cytotoxicity
C0011854||type 1 diabetes
C0242629||CD8(+) T cells
C0024264||lymphocytes
C0011847||diabetes
C3539881||interferon-γ
C0242629||CD8(+) T-cell
C1326120||activation
C0150544||care
C0011847||diabetic
C0184661||intervention
C0449445||approaches
C0443264||modulating
C3539881||interferon-γ